T echnological advances have led to innovative insulin delivery systems for patients with type 1 diabetes mellitus. In particular, the combination of miniature engineering and software algorithms contained in continuous subcutaneous insulin infusion (CSII) system pumps provide the user and the healthcare practitioner with an opportunity to review and adjust blood glucose (BG) levels according to system feedback, and to modify or programme their regimen according to their needs. While CSII pumps record a number of data parameters such as BG level, carbohydrate intake, activity and insulin delivered, these data are generally 'locked in' and can only be accessed by uploading to a cloud-based system, thus information is not contemporaneous. The Cellnovo Diabetes Management System (Cellnovo, Bridgend, UK) allows data to be transmitted securely and wirelessly in real time to a secure server, which is then retrieved by an online platform, the Cellnovo Online platform, enabling continuous access by the user and by clinicians. In this article, the authors describe a retrospective review of the patient data automatically uploaded to the Cellnovo Online platform. Baseline clinical and demographic characteristics collected at the start of pump therapy are shown for all patients, and BG data from a sub-cohort of patients who have been using the system for at least 6 months and who take and record an average of three BG level tests per day are presented to demonstrate glycaemic data over time.
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(BG) meter and automatic connectivity to secure servers. 12 The system's unique features and advantages have been outlined previously. 12 Users of the Cellnovo System receive a personal login to the secure mobile diabetes management portal where they can access automatically collected data in order to review their treatment regimen and determine if adjustments are required. The patient's healthcare professional (HCP) can access data pertaining to their latest recorded blood sugar, average blood sugar, insulin dosing, hypoglycaemia frequency and blood testing routine, facilitating early intervention where necessary. Working in conjunction with the patient, data can be also analysed to identify trends, patterns and glycaemic status; this interactivity using real-time data can facilitate greater patient self-management and allow clinic visits to be focused on current and accurate information. 12 
Retrospective data study
Having real-time data from patients using the Cellnovo pump during their everyday life presents an opportunity to gain a deep understanding of their clinical status on a daily basis and over time. The primary aims of this retrospective data study therefore were:
• To review and present clinical and demographic characteristics of the entire cohort enrolled in the Cellnovo database and establish a profile of patients at their first month of pump use. This will enable clinicians to compare these characteristics with those in their own daily clinical practice at pump initiation.
• To analyse a number of glycaemic parameters from a sub-cohort of pump users.
Methods

Data collection
Prior to starting on the Cellnovo pump, patients provided written informed consent to the anonymous collection, storage and use of their demographic and clinical data in the Cellnovo Diabetes Management System. This baseline data are recorded when the patient starts pump therapy; thereafter, BG measurements and hourly basal and bolus doses delivered are recorded.
Full cohort
Data were retrieved from January 2013 to September 2017; the baseline demographic and clinical data of the 599 patients (worldwide) reviewed included:
• age, gender;
• total daily dose (TDD), ratio of daily basal and bolus to the TDD in the first month of pump use;
• duration of T1DM where available;
• HbA1c; and
• the number of BG measurements per day in the first month of pump use.
Sub-cohort
From this data set, we retrieved a smaller cohort of 166 patients who had used the pump for at least 6 months and had recorded their BG at least three times a day on average; this was to ensure a sufficient duration of pump use and enough glycaemic data to undertake analysis. In this subcohort, we analysed:
• mean HbA1c;
• mean BG and standard deviation (SD) to express variability;
• number of hypoglycaemic events per week, comparing first and last analysed month of data; and
• the median follow-up time for this cohort of 1 year (range 6-41 months).
Statistical analysis
Data were tested for normality using the Shapiro-Wilk test. The paired Student's t-test and Wilcoxon rank-sum test were used as they were appropriate to identify changes in mean and SD of BG measurements. A p value of less than 0.05 was taken to indicate significance.
Results
Full cohort
Data were retrieved from January 2013 to September 2017. Table 1 shows the baseline demographic and clinical characteristics of the full cohort of patients (n=599), 495 (82.6%) of whom were adults. The mean age at start of pump therapy was 8 years in children, 14.5 years in adolescents and 39.1 years in adults.
Insulin total daily dose
From baseline to month 1, mean TDD of insulin in the first month was 38.1 ± 14.6 IU/day; the TDD was lowest in children (28.4 ± 12.5 IU/ day), and highest in adolescents (48.2 ± 17.5 IU/day). The bolus doses as a fraction of the TDD were highest in children (64%) and lowest in adults (55%). 
HbA1c level at baseline
The mean HbA1c at baseline ( in adolescents and 7.81% in adults. Table 2 shows HbA1c readings by age group. Of the 599 patients, data were available for 584 patients (57 children, 44 adolescents and 483 adults). The percentage of patients in the children and adult age groups with an HbA1c below 7% was largely similar (18% and 19%, respectively), whereas just over half (54%) of the adolescents had an HbA1c above 8% at pump initiation.
Sub-cohort
In total, 166 patients were included in the sub-cohort (16 children, 7 adolescents and 143 adults). Due to small numbers, neither HbA1c
(children and adolescent group) nor mean BG and SD (adolescent group) were analysed. Table 3 shows baseline HbA1c values as percentages (range <7->9%).
HbA1c level
Of the 166 patients in the sub-cohort, HbA1c data were recorded for 151 patients (15 children, 6 adolescents and 130 adults). Overall, 34 patients (20.5%) had two HbA1c measurements more than 90 days apart (mean follow-up time 10 months, range 3.5-25.7 months); of these, 30 were adults. In this adult group there was a significant reduction in HbA1c of 0.54% (p=0.002; Table 4 ). 
Hypoglycaemic events
Discussion
The Cellnovo Online platform is not a registry, but the data available provide clinical and lifestyle information about the patient's daily life.
This review describes the profile of patients in multiple sites who are registered on the Cellnovo Diabetes Management System.
Results from the median follow-up of 1 year in the sub-cohort show a significant improvement in HbA1c and a downward trend in children, and a decrease in hypoglycaemia frequency of approximately one event per week in adolescents and adults. Mean BG levels have remained the same for children and adolescents with a very slight increase on average for adults. While BG variability has not decreased, this analysis has to be interpreted carefully as it is real-life retrospective data. BG measurements can be biased; for example, if a patient is feeling unwell, they may measure BG more frequently, whereas when they feel well, they may reduce the number of measurements they undertake. Encouragingly, however, mean BG improved by 14.6% of adult pump users.
Retrospective results from two studies of the Omnipod ® System (Insulet Corporation, Billerica, MA, US) found both similarities and differences when compared with the data reported here. For example, in our cohort 7.46% of patients were aged under 18 years at pump initiation, whereas the Austrian and German Diabetes-patient-documentation (DPV) registry showed a larger proportion of children (74% aged <20 years). 21 An American study showed just over one-third of patients were aged under 18 years, with a mean age of 29 years. 17 The differences between these studies and ours may be explained by differences in criteria for pump prescription between countries and the growing number of children using pump therapy, particularly in the US. 22 The mean duration of diabetes in the adult group in the present study was the same as the American study, with slight differences among adolescents and children. In the DPV registry, 57% of patients had diabetes for less than 5 years due to the higher proportion of children and adolescents using the pump.
In this review, the TDD of insulin at baseline for adults was low (38 IU/day), there was no significant difference between pumps at 1 year after pump start, the overall decrease in HbA1c was no more than our result of 0.5% (reduction from 8.7 to 8.2%). 16 Johnson et al. reviewed data pertaining to 345 children (aged <18 years) on the Western Australian Childhood Diabetes Database (WACDD) over a 7-year period and found that the mean HbA1c reduction was 0.6%, which remained significant throughout the 7 years of follow up. 24 Severe hypoglycaemia reduced from 14.7 to 7.2 events per 100 patient-years (p<0.001). In another 7-year follow-up study, Mameli et al. showed an improvement in HbA1c of 0.5% at year 1, and further improvement at year 7, with a significant decrease in severe hypoglycaemia of 0.5 to 0.9%. 25 Sherr et al. explored metabolic control in young people, using data from three diabetes registries; the Austrian and German DPV (n=26,198), T1D Exchange (T1DX; n=13,755) and the National Paediatric Diabetes Audit (NPDA; n=14,457). 26 Pooled analysis of the data showed that pump use was associated with a lower mean . 27 Johnson et al. also demonstrated that the number of events dropped by 50% to that experienced in the year before pump therapy (14.7 to 7.2 events per 100 patient-years; p<0.001).
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Limitations
It is acknowledged that the primary aim of the database is to help patients and HCPs manage insulin dose adaptation in real-time with respect to different daily life situations, rather than to study the glycaemic effect of the system. While real-time data are recorded automatically by the system, BG measurements are entered by the patient, so may be biased towards those times when the patient feels unwell. This may explain the lack of improvement in either mean BG or BG variability. In addition, as this is a retrospective review of data, it is not possible to explore anomalies in data, or to discern the confounding variables.
Conclusion
The results from real-life data showed a significant and meaningful improvement in HbA1c -a decrease of 0.54% -and hypoglycaemia frequency at 1 year follow-up. Mean BG levels remained the same for children and adolescents with a very slight increase on average for adults, and while BG variability has not decreased, this is real-life retrospective data.
Further studies are needed to evaluate all the benefits of the system.
To this end, for clinical and regulatory purposes, we plan to undertake prospective studies to assess glycaemic control and outcomes, as well as evaluating quality of life and patient feedback in clinical situations with the involvement of HCPs. 
